University of Iowa

uiowa.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

272

Active

45

Phase 3

8

Total enrollment

67,713

Pipeline matrix

Showing 19 of 19 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Metronidazole 0.75% Topical Gel1
Metronidazole 0.75% Topical Cream1
Intravenous administered opioid1
Epidural administered opioid1
Dostarlimab2
Salsalate Oral2
Doxycycline Hyclate1
Lutetium Lu 177 dotatate therapy1
Fish Oil Concentrate, 1000 Mg Oral1
Psilocybin1
Ketamine2
Terazosin1
Terazosine1
Ascorbate1
Salsalate 750 MG Oral Tablet [DISALCID]1
Acetylcholine1
Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine1
IV adenosine1
IV diltiazem1

Next readouts

  • 2023-03-01
  • 2025-03-18
  • 2025-08-12
  • 2026-06
  • 2026-07-31
  • 2026-12-30
  • 2026-12-31
  • 2026-12-31
  • 2027-02-01
  • 2027-05-01

Top conditions

  • Healthy14
  • Knee Osteoarthritis10
  • Depression6
  • Obesity6
  • Hypertension5
  • Multiple Sclerosis5
  • Cardiovascular Diseases4
  • Charcot Marie Tooth Disease3

Frequently asked questions about University of Iowa

How many clinical trials does University of Iowa have on ClinicalTrials.gov?
University of Iowa is listed as the lead sponsor on 272 clinical trials in ClinicalTrials.gov, 45 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Iowa's trials are in Phase 3?
8 of University of Iowa's trials are in Phase 3, spread across 19 active drug programs.
What therapeutic areas does University of Iowa focus on?
University of Iowa's most-studied conditions on ClinicalTrials.gov are Healthy, Knee Osteoarthritis, Depression, Obesity, Hypertension.
When are University of Iowa's next clinical trial readouts?
University of Iowa has 10 upcoming primary-completion readouts tracked here; the soonest is “Target Engagement of Terazosin in Healthy Adults”, expected around 2023-03-01.